DM
MNPR icon

Deerfield Management’s Monopar Therapeutics MNPR Stock Holding History

Deerfield Management’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.7M Buy
323,745
+153,187
+90% +$9.25M 0.21% 64
2025
Q4 		$11.1M Buy
170,558
+10,793
+7% +$882K 0.14% 66
2025
Q3 		$13M Buy
+159,765
New +$7.14M 0.2% 64

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deerfield Management's MNPR Position: Q1 2026 in Review

Deerfield Management increased its Monopar Therapeutics (MNPR) stake by 90% in Q1 2026, buying an estimated $9.25M and bringing the position to 323,745 shares worth $17.7M. The position accounts for 0.21% of the portfolio, ranked #64.

Deerfield Management first reported a position in MNPR in Q3 2025 and has held it in 3 quarters since. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Deerfield Management held 323,745 shares of Monopar Therapeutics worth $17.7M as of Q1 2026.
  • Deerfield Management bought 153,187 Monopar Therapeutics shares in Q1 2026, an estimated $9.25M.
  • Monopar Therapeutics made up 0.21% of Deerfield Management's portfolio in Q1 2026, its #64 holding.
  • Deerfield Management first reported a position in Monopar Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Deerfield Management's 13F filing for Q1 2026, filed 15 May 2026.